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Background: A suboptimal bone accrual in young individuals with cystic ﬁbrosis (CF) may be related to the development of a premature CF-related
bone disease. Dual energy X-ray absorptiometry (DXA) is the mainstream measure of bone health; however, the inﬂuence of body size and lean tissue
mass (LTM) on bone data is poorly interpreted.
Methods: Total body dual-energy X-ray absorptiometry (DXA) measurements of bone mineral content (BMC) and LTM in 53 individuals with CF
(7.00–17.99 years) were compared to 53 sex-matched controls. BMC, height, and LTM in relation to height and BMC Z-scores were calculated
and used in a 4-step algorithm.
Results: Pubertal females with CF had less total body BMC for age (p = 0.02); pre-pubertal males (p = 0.05) and pubertal females with CF
(p = 0.03) were shorter; and pubertal females with CF showed less total body BMC for LTM (p = 0.01).
Conclusions: The algorithm showed the following: (1) prior to puberty lowered total body BMC was primarily due to short stature, (2) LTM was
appropriate for body size, and (3) pubertal females with CF had signiﬁcantly less total body BMC for their LTM. Longer controlled trials are
needed to clinically interpret CF-related bone disease using DXA derived data that considers patient size and body composition.
© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; BMC; Height; LTM; DXA; Algorithm1. Introduction
Adults with CF have an increased risk of fracture [1,2]. This
increased risk may be linked to an inadequate bone mineral
accrual during the childhood years, and be independently
associated with a reduced amount of lean tissue mass (LTM) [3].
Dual-energy X-ray absorptiometry (DXA) has been a useful
modality to gain an increased understanding of bone health in
individuals with CF [3–10]. Clinical evaluations are based on⁎ Corresponding author at: Children's Nutrition Research Centre, Queensland
Children's Medical Research Institute, Old Milk Kitchen, Cnr of Fourth and
Back Roads, The University of Queensland, Herston, QLD 4029, Australia.
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1569-1993/© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. Aareal bone mineral density (aBMD) as a function of bone mineral
content (BMC) in the projected bone area, measured in g/cm2
(aBMD = BMC/bone area, g/cm2), and compared to age- and
sex-matched reference data. Short stature is common in individ-
uals with CF [3,5]. The small body size will result in reduced
total body aBMD and BMC, which can be misinterpreted as an
abnormally low result when compared to typically developing age
and sex specific reference data [11–14]. The International Society
of Clinical Densitometry (ISCD) 2013 position statement,
therefore, recommends to adjust for stature in the interpretation
of paediatric bone health [15], but this is yet to be implemented in
many clinical settings.
When adjusted for body size, aBMD and BMC results are
similar in individuals with CF compared to controls [5,6,8,9].ll rights reserved.
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to be an independent predictor of height adjusted aBMD [3].
Moreover, aBMD results that have been adjusted for height and
LTM, to explain resultant bone deficits as a functional muscle–
bone relationship, reveal no significant differences in total
body and regional aBMD in individuals with CF compared to
matched controls [5].
Applying the 4-step algorithm of Högler et al. [12], which
considers height and LTM when interpreting DXA data, may
account for individual differences in body size and LTM, and
allow for the examination of muscle and bone relationships.
Our study aimed to assess if low aBMD, measured by DXA,
was due to: an intrinsic bone problem, by way of reduced BMC;
reduced LTM; or a combination of both, in young individuals
with CF. This allowed the following important questions to be
clinically addressed: (1) does BMC develop appropriately for the
associated LTM; and (2) is there a need to place emphasis on
increasing BMC by increasing LTM?
2. Methods
2.1. Subjects
Individuals with CF, aged between 7.00 and 17.99 years
who attended the Royal Children's Hospital (RCH), Brisbane,
Australia, were invited to participate in this cross-sectional
study of bone health in CF. The diagnosis of CF had been
confirmed by an elevated sweat chloride test. Individuals with
CF were excluded if they had a primary bone disorder, or were
awaiting lung transplantation. A comparison was made to
healthy controls, of the same age, recruited from local primary
and secondary schools in the Brisbane region. Exclusion
criteria for the control group included: chronic medical
conditions known to affect growth, nutritional status or bone
health; use of oral corticosteroids ≥2 weeks; and/or immo-
bilisation ≥ 1 week, in the preceding 12 months of the
recruitment period. Only controls of European-Australian
ancestry were included so as to be comparable to the CF cohort.
Approval for the study was obtained from the Medical
Research Ethics Committee, The University of Queensland
and the Royal Children's Hospital and Health Service District
Ethics Committee. Informed consent to participate was
obtained by all participants prior to testing. Assent by oral
agreement was given by participants under 10 years of age, and
written informed consent was provided by all legal guardians
and participants over the age of 10 years.
2.2. Clinical assessment
Height was measured (Magnimeter, Raven Equipment, UK)
to be 1 mm and weight was determined to be 0.05 kg (Tanita
BWB-600 Wedderburn Scales, Australia). BMI (kg/m2) was
calculated as weight/height2. Standard deviation Z-scores for
height, weight and BMI for each subject were calculated relative
to the Centers for Disease Control and Prevention (CDC) 2000
growth data [16]. Spirometry testing was performed only in the
CF cohort at the RCH respiratory laboratory. The best FVC andFEV1 were recorded and expressed as percentage predicted [17].
Left hand-wrist X-rays were obtained for the determination of
bone ages, calculated by one reader (DB) using the Tanner–
Whitehouse (TW3) method [18]. Self-assessed pubertal status
was attained via pictorial illustrations [19], where puberty was
defined as Tanner stage ≥2. Vitamin D levels were measured
[20]. A vitamin D level b 50 nmol/L [21] was used to determine
vitamin D insufficiency.
The following data were collected via retrospective hospital
chart reviews or history recall: genotype; pancreatic sufficiency
status; oral and/or inhaled corticosteroid use for the 6 months
prior to the project; and the presence of pseudomonas aerial
infection. Incidence of any fractures in the 6 months prior to
testing date was questioned directly for all subjects.
2.3. Densitometry
Using standard procedures, a total body (including head)
DXA scan (Prodigy, GE Medical Systems, LUNAR, Madison,
WI, USA) was used to obtain total body BMC (g) and LTM (g)
for all study participants. Scans of the anterior posterior (AP)
spines L1–L4 were additionally acquired. All results were
reported as mean ± SD. The departmental operator precisions
for the measured sites were 1% for the total body scans across
the study. Daily calibration of the DXA was performed on the
morning prior to each measurement using an aluminium spine
phantom. All images were acquired and analysed by the
principal investigator (DB) using the manufacturer's paediatric
software (enCORE, version 11.4).
2.4. 4-step algorithm
This algorithm provides a classification to better describe
CF-related bone disease when using total body DXA data,
according to a possible biomechanical pathogenesis [22]. The
algorithm is total body specific as it supplements the problematic
total body age aBMD Z-score in abnormally sized individuals.
Initially, height is considered, then any low aBMD may be the
result of low bone accrual (BMC), low LTM or a combination of
both BMC and LTM. To determine if a low BMC was body size
related, total body BMCZ-scores (Australian paediatric reference
database [12]) and height Z-scores [16] were used with the 4-step
algorithm [12]. Log–log regression was used to normalise LTM
for height and total body BMC for LTM using the same
Australian paediatric database. The value for each Z-score was
assigned as: low (b−1); normal (≥−1 to 1); or high (N1). For
example, when following steps 1 to 4 in Fig. 1, a low BMC for
age, when accounted for height, may result from poor bone
accrual, low LTM, or a combination of both scenarios BMC and
LTM, respectively.
The AP spine data was not used in the algorithm as the: (1)
generation of spine BMC is based on an estimate of fat mass of
the adjacent soft tissue. The inhomogeneity of fat distribution in
the soft tissue overlying and adjacent to the AP spine causes
large variations in BMC [23,24]; (2) biomechanical relation-
ships of BMC to LTM are specific to the striated skeletal
muscle and bone physiology, largely at the periosteal bone
Fig. 1. The guidelines of the 4 step algorithm interpretation for DXA. Firstly, the procedure assesses height and total body BMC for age. Thereafter, participants
are classified as “low total body BMC considered for height” and are further assessed for LTM for height and total body BMC for LTM. Combining steps 3 and 4
concludes a possible biomechanical pathogenesis of a CF-related bone disease.
Adapted from Hogler et al. [12] with permission.
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force generated from striated LTM make specific muscle and
bone relationships at the AP spine, primarily trabecular bone,
difficult to explore.
2.5. Statistics
Student's t-tests were used to compare CF subjects to
controls for all clinical and densitometry measurements. The
groups were stratified according to sex and pubertal status to
better account for the sexual dimorphism in skeletal growth
during puberty [26]. Data were analysed using SPSS version
18. Means and standard deviations (SD) were reported.
Significance for all data was set to a p value of b0.05.Table 1
Subject characteristics for CF and control participants, stratified by Tanner stage an
Pre-pubertal Males
(Tanner stage 1) CF (7) Control (7)
Chronological age (years) 10.01 (1.35) 9.85 (1.31)
Bone age (years) 9.46 (1.75) 10.62 (1.44)
Height Z-score 0.13 (0.74) 1.08 (0.88)
Weight Z-score 0.18 (0.74) 1.14 (1.88)
FEV1 (% predicted) 84 (17) –
Pubertal Males
(Tanner stages 2–5) CF (12) Control (12)
Chronological age (years) 14.20 (1.93) 14.51 (1.83)
Bone age (years) 13.79 (2.05) a 14.77 (1.81)
Height Z-score −0.30 (0.93) 0.43 (1.00)
Weight Z-score −0.28 (0.74) 0.54 (0.82)
FEV1 (% predicted) 80 (28) –
a n = 11.3. Results
3.1. Subjects
Data were available for 53 individuals with CF and 53 controls
(Table 1). Subjects were stratified by sex and Tanner stage
(pre-pubertal: CF = 16(9 F), controls = 18(11 F); pubertal:
CF = 37(25 F), controls = 35(23 F)). The pre-pubertal males
with CF were significantly shorter compared to the pre-pubertal
male controls. The pre-pubertal females showed no significant
differences between any of the anthropometric variables for
females with CF compared to pre-pubertal female controls. At
puberty, the females with CF were height and weight compro-
mised compared to the female controls. The pubertal males withd sex.
Females
p CF (9) Control (11) p
ns 9.50 (1.32) 8.53 (1.47) ns
ns 8.83 (2.25) 8.01 (1.75) ns
0.05 −0.34 (0.96) 0.07 (1.01) ns
ns −0.37 (0.82) 0.15 (1.01) ns
– 76 (22) – –
Females
p CF (25) Control (23) p
ns 14.45 (1.98) 14.55 (1.67) ns
ns 14.14 (1.78) 14.44 (1.73) ns
ns −0.40 (1.21) 0.38 (1.17) 0.03
0.02 −0.30 (1.07) 0.40 (1.20) 0.04
– 83 (20) – –
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controls. Chronological age was not significantly different from
bone age by group or stratified by sex, and a later menarcheal age
in pubertal females with CF was not significantly different from
that of the controls (data not shown); hence results are reported as
chronological age. The individuals with CF presented with a mild
lung disease both at pre-puberty (mean FEV1 of 84 ± 17% and
76 ± 22%) and puberty (mean FEV1 of 80 ± 27% and 83 ± 20%)
for males and females, respectively.
3.2. Clinical assessment
The genotypes of the participants with CF were identified as
31 as homozygous for delta-F508 (58%), 18 as heterozygous
for delta-F508 (34%) and 4 without delta-F508 allele (8%). Of
the participants with CF only 3 (6%) were pancreatic sufficient;
16 (30%) were pseudomonas aeruginosa free; CF-related
diabetes was diagnosed in one (2%); and CF-related liver
disease was diagnosed in 3 (6%). Inhaled glucocorticosteroids
(GCS) were taken by at least 34 participants with CF (14 charts
were unavailable; 5 had no inhaled GCS). In addition to inhaled
GCS, oral or intravenous GCS were taken by 4 of these
participants with CF, intermittently or at inpatient tune-ups. All
patients took, at minimum, fat soluble vitamins A, E and K and
were advised to performed daily hypertonic saline combined
with chest physiotherapy through a positive expiratory pressure
mask. The 37 participants with CF with chronically colonised
pseudomonas aeruginosa or burkholderia cepacia received
regular broad spectrum antibiotics orally, by inhalation or
intravenously, as part of the inpatient tune-ups. Three parti-
cipants were treated with 20 mg/kg of body weight of
ursodeoxycholic acid daily for CF-related liver disease. No
fracture incidents were reported during the time of testing. Of
the controls, no participants reported an intake of inhaled or
oral GCS prescription or fracture incidence during the time of
testing. Vitamin D (25-OHD) levels were within normal range,
and not different between the CF and controls as a group and inTable 2
Densitometry data of total body (TB) and AP spines (L1–L4) for CF and control pa
Pre-pubertal Males
(Tanner stage 1) CF (7) Control (7)
TB aBMD Z-score 0.4 (0.4) 0.1 (0.5)
TB BMC (g) 1181.5 (192.3) 1249.3 (277.1)
TB bone area (cm2) 1300.3 (181.8) 1406.9 (263.2)
TB fat mass (kg) 6.7 (3.4) 8.8 (5.6)
TB LTM (kg) 25.6 (4.1) 27.0 (5.2)
L1–L4 aBMD Z-score −0.4 (0.4) −0.9 (0.5)
Pubertal Males
(Tanner stages 2–5) CF (12) Control (12)
TB aBMD Z-score −0.2 (1.2) 0.4 (1.1)
TB BMC (g) 1937.9 (608.6) 2395.8 (853.6)
TB bone area (cm2) 1863.7 (400.7) 2191.1 (470.8)
TB fat mass (kg) 7.4 (2.2) 10.8 (5.9)
TB LTM (kg) 40.3 (9.8) 47.1 (13.7)
L1–L4 aBMD Z-score −0.5 (1.5) 0.4 (1.5)males. Females with CF had significantly lower (p = 0.01)
mean vitamin D (58.3 ± 19.2 nmol/L) compared to female
controls (76.3 ± 22.9 nmol/L).3.3. Densitometry
There were no significant differences in aBMD age Z-scores
and raw ancillary data between the respective controls and
males with CF, nor with pre-pubertal females with CF
(Table 2). The pubertal females with CF had lower total body
aBMD Z-scores (p = 0.03), BMC (p = 0.01), and fat mass
(p = 0.05); a smaller bone area (p = 0.01); and lower AP spine
aBMD (L1–L4) Z-scores compared to the pubertal female
controls (Table 2).
When classified according to delta F508 genotype, the mean
BMD Z-scores were not significantly different in those
individuals who were homozygous (−0.11 ± 0.16) or hetero-
zygous (−0.23 ± 0.31) compared to those individuals who had
no delta F508 allele (−0.60 ± 0.55), respectively; p b 0.05
(Fig. 2A). Mean BMC Z-scores were not significantly different
in those individuals who were: homozygous (−0.57 ± 0.21) or
heterozygous (−0.54 ± 0.45), compared to those individuals
who had no delta F508 allele (−0.68 ± 0.57), respectively;
p b 0.05 (Fig. 2B), additionally stratified by sex; homozygous
(female:−0.75 ± 0.31, male: −0.28 ± 0.20) or heterozygous
(female:−0.87 ± 0.59, male: 0.31 ± 0.34), compared to those
individuals who had no delta F508 allele (female:−0.76 ± 1.05,
male: −0.60 ± 0.92), respectively; p b 0.05 (Fig. 2C).3.4. 4-step algorithm
A summary of the 4-step algorithm outcomes in the CF
compared to the control cohorts is shown in Fig. 1 and Table 3.
Our results are site specific to total body DXA scans and
cannot, therefore, be generalised to other DXA scanned sites.rticipants, stratified by Tanner stage and sex.
Females
p CF (9) Control (11) p
ns 0.4 (0.5) 0.3 (0.6) ns
ns 1086.9 (247.0) 1001.7 (244.0) ns
ns 1193.2 (208.6) 1142 (216.6) ns
ns 6.6 (3.5) 7.8 (4.9) ns
ns 21.4 (3.2) 20.0 (3.1) ns
ns −0.3 (0.9) −0.0 (0.8) ns
Females
p CF (25) Control (23) p
ns −0.6 (1.1) 0.1 (1.0) 0.03
ns 1782.4 (439.6) 2127.1 (524.1) 0.01
ns 1724.2 (285.1) 1967.7 (313.1) 0.01
ns 12.6 (7.0) 16.8 (7.4) 0.05
ns 33.9 (5.9) 35.3 (5.9) ns
ns −0.9 (1.8) 0.1 (1.3) 0.03
Fig. 2. Total body Z-scores for each CF genotype category: (A) BMD as a
group (homozygous: n = 31; heterozygous: n = 18; absent: n = 4); (B) bone
mineral content (BMC) as a group, and (C) BMC by sex (homozygous: n = 19
F/12 M; heterozygous: n = 13 F/5 M; absent: n = 2 F/2 M). Mean ± SD,
*p b 0.05.
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The pre-pubertal males with CF had significantly more LTM
(p = 0.05), despite being shorter (p = 0.05), compared to the
pre-pubertal male controls. Moreover, the pre-pubertal males
with CF showed adequate total body BMC for this amount ofLTM (Table 3). There were no significant differences between
pre-pubertal females with CF and pre-pubertal female controls
(Table 3).3.4.2. Pubertal; by sex
In the pubertal groups, males with CF tended to show lower
Z-scores in all 4-steps of the algorithm: total body BMC for
age; height for age; LTM for height; and total body BMC for
LTM, compared to the male controls (Table 3). However, the
Z-scores were not significantly different compared to the male
controls.
The pubertal females with CF had less total body BMC for
age (p = 0.04) and were shorter (p = 0.03) compared to the
pubertal female controls. LTM was not different between the
females with CF and the controls. However, pubertal females
with CF had significantly less total body BMC for the amount
of LTM (p b 0.01) than the pubertal female controls (Table 3).4. Discussion
By using the algorithm, our results provide a more
comprehensive analysis of low BMC for age in young
individuals with CF by assessing the DXA total body data
using an algorithm (Fig. 1) that considers the participants'
height and LTM. The algorithm helped overcome the problem
of using total body “areal” BMD age Z-scores that are
problematic in abnormally sized individuals, and, therefore, is
relevant to clinically short individuals with CF. Although a
“headless” total body BMD is recommended by the ISCD [15],
we reported total body BMC including head. The paediatric
head aBMD is higher than the aBMD of other anatomical
regions due to the disproportionally larger bone area [27], and
may mask low aBMD for age results; especially if the limbs or
trunk regions are low. The head BMC, however, is not
significantly higher than the BMC of other anatomical regions,
and does not impact total body BMC [27]. Moreover, the
algorithm adopted the ISCD recommendations for the clinical
assessment of paediatric bone health, as both height and LTM
were considered [15].
Compared to their respective controls, pre-pubertal and
pubertal males with CF showed lower total body BMC for age,
mainly due to their shorter stature. LTM for height was higher
in the pre-pubertal males with CF compared to controls, but
the controls were considerably taller. Nevertheless, both
pre-pubertal and pubertal males with CF showed adequate
amounts of LTM for their shorter height, combined with
adequate total body BMC for these amounts of LTM to suggest
a normal adaptation of total body BMC when considered for
height and LTM. A difference was observed in the female CF
cohort. The pre-pubertal females with CF showed trends of
lowered total body BMC for LTM that was not different from
that of the controls to suggest a normal adaptation of total body
BMC when considered for height and LTM. However, our
findings of a reduced total body BMC for LTM in the pubertal
females with CF, despite considering their shorter height, may
be suggestive of a primary bone deficit.
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discrepancies in the clinical reporting of total body DXA
results that do not consider height, where low BMC may be
mistaken from what is, likely, normal growing bone relative to
height. Alternative methods of analysis for total body DXA
data that have included results of BMC for age in individuals
with CF also report a reduced prevalence of low total body
BMC for age when adjusted for height. In 134 individuals with
CF, Laursen et al. [8] showed that short bones were a main
reason for reduced total body BMC for age. Sood et al. [9]
observed that total body BMC was not different in 29 children
with CF compared to age and size matched controls. Grey and
coworkers [28] reported a 38% prevalence of low total body
BMC for age in young individuals with CF, where the height
Z-score was a significant predictor of the low total body BMC
observed.
The lower total body BMC when considered for LTM
shown in our study is supported by previous work using DXA
data, where height and LTM strongly influence BMC [3,5,6],
and any lowered total body BMC that is associated with LTM
emerges in the pubertal years [3,5,10,29,30]. Importantly, the
combined reductions in both total body BMC and LTM may
also be reflective of CF disease severity [31]. These combined
reductions were not seen in our study cohort. Despite the
complex pathogenesis of a CF-related bone disease, the
importance of a biomechanical total body BMC and LTM
relationship, already reported in healthy controls [32–34], is
being recognised in young individuals with CF [3–6,10].
However, algorithm data that explores sub-region specific LTM
and BMC relationships i.e., DXA data of AP spine, in
CF-related bone disease warrants future investigation.
The cohorts in our study were classified as having a mild CF
disease, and were well-nourished with similar levels of physical
activity compared to the controls (data not shown). Mean total
body aBMD and BMC Z-scores were not significantly different
according to the presence (homozygous or heterozygous) of the
delta F508 genotype compared to those who did not have the
delta F508 mutation. Whilst the small cohort with an absence
(n = 4) compared to those with the presence (n = 49) of the
delta F508 genotype may have greatly influenced our results,
similar findings were reported by Seremet-Gaudelus et al. [10]
in their larger cohort of young individuals with mild disease
and normal nutritional status. However, an increased risk of
reduced aBMD/BMC in the presence or absence of the delta
F508 has been strongly reported [6,35]. Further work using the
algorithm to explore low aBMD/BMC stratified according to
genotype and specific body sub-regions is warranted.
Whilst lowered levels of vitamin D in the females with CF
may have influenced the muscle and bone relationship, samples
were only collected in 50% of this cohort. Moreover, the later
menarcheal age in the pubertal females with CF, compared to
the controls, may contribute to these findings; however,
chronological age was not significantly different from bone
age (data not shown) and, therefore, adjusted bone age data
were not generated. However, any variations in disease severity
within the participants with CF may lead to lower/different
physical activity and nutritional status, compared to the controls
133D.S.K. Brookes et al. / Journal of Cystic Fibrosis 14 (2015) 127–134that may negatively impact LTM and, subsequently, BMC.
Moreover, the small sample size in our study, particularly when
stratifying for both sex and pubertal status, may have
potentially affected the statistical significances observed. The
impact of these variations on the muscle and bone relationship
in a larger CF cohort warrants future investigation. These data
further support the need to, at least, adjust DXA total body
BMC for height, and consider the influence of LTM on bone
development.
5. Conclusion
The algorithm showed that prior to puberty total body BMC
is not compromised for the associated LTM in these parti-
cipants with CF, and any lower total body BMC is primarily
due to short stature to suggest a normal adaptation of total body
BMC when considered for height and LTM. However, our
findings of inadequate total body BMC for LTM in the pubertal
females with CF, despite considering height, may be suggestive
of a primary bone deficit. A clinical focus may be on increasing
BMC, independently of and in addition to, maintaining LTM.
Particular attention should be on females with CF where the
skeleton appears to adapt poorly to muscle strain in adoles-
cence. Further investigation to identify factors that influence
the development of bone and LTM such as: vitamin D; fat
mass; pubertal hormones; inflammatory cytokines and medica-
tion (e.g. glucocorticoid therapy) for total body and specific
anatomical regions is warranted. Our study shows the
importance of considering total body BMC for height and
LTM in young individuals with CF to prevent an erroneous
interpretation of DXA data, and provide an important clinical
assessment tool.
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